As part of our ongoing series focussing on medicines in Australia, we have added a product review of the use of Olaparib for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior therapy.
This review presents the efficacy and tolerability data from the PROfound trial and information related to the testing of men at diagnosis of mCRPC for their BRCA mutation status. Commentary has been provided by Dr Ben Tran, a consultant medical oncologist in Melbourne, with appointments at Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research.
Please login below to download this issue (PDF)